<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36402659</PMID><DateCompleted><Year>2023</Year><Month>04</Month><Day>03</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-2518</ISSN><JournalIssue CitedMedium="Internet"><Volume>41 Suppl 1</Volume><Issue>Suppl 1</Issue><PubDate><Year>2023</Year><Month>Apr</Month><Day>06</Day></PubDate></JournalIssue><Title>Vaccine</Title><ISOAbbreviation>Vaccine</ISOAbbreviation></Journal><ArticleTitle>Outbreak response strategies with type 2-containing oral poliovirus vaccines.</ArticleTitle><Pagination><StartPage>A142</StartPage><EndPage>A152</EndPage><MedlinePgn>A142-A152</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.vaccine.2022.10.060</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0264-410X(22)01336-6</ELocationID><Abstract><AbstractText>Despite exhaustive and fully-financed plans to manage the risks of globally coordinated cessation of oral poliovirus vaccine (OPV) containing type 2 (OPV2) prior to 2016, as of 2022, extensive, continued transmission of circulating vaccine-derived polioviruses (cVDPVs) type 2 (cVDPV2) remains. Notably, cumulative cases caused by cVDPV2 since 2016 now exceed 2,500. Earlier analyses explored the implications of using different vaccine formulations to respond to cVDPV2 outbreaks and demonstrated how different properties of novel OPV2 (nOPV2) might affect its performance compared to Sabin monovalent OPV2 (mOPV2). These prior analyses used fixed assumptions for how outbreak response would occur, but outbreak response implementation can change. We update an existing global poliovirus transmission model to explore different options for responding with different vaccines and assumptions about scope, delays, immunization intensity, target age groups, and number of rounds. Our findings suggest that in order to successfully stop all cVDPV2 transmission globally, countries and the Global Polio Eradication Initiative need to address the deficiencies in emergency outbreak response policy and implementation. The polio program must urgently act to substantially reduce response time, target larger populations - particularly in high transmission areas - and achieve high coverage with improved access to under-vaccinated subpopulations. Given the limited supplies of nOPV2 at the present, using mOPV2 intensively immediately, followed by nOPV2 intensively if needed and when sufficient quantities become available, substantially increases the probability of ending cVDPV2 transmission globally.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022. Published by Elsevier Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kalkowska</LastName><ForeName>Dominika A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Kid Risk, Inc., Orlando, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wassilak</LastName><ForeName>Steven G F</ForeName><Initials>SGF</Initials><AffiliationInfo><Affiliation>Global Immunization Division, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pallansch</LastName><ForeName>Mark A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burns</LastName><ForeName>Cara C</ForeName><Initials>CC</Initials><AffiliationInfo><Affiliation>Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wiesen</LastName><ForeName>Eric</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Global Immunization Division, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Durry</LastName><ForeName>Elias</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Global Immunization Division, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Badizadegan</LastName><ForeName>Kamran</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Kid Risk, Inc., Orlando, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thompson</LastName><ForeName>Kimberly M</ForeName><Initials>KM</Initials><AffiliationInfo><Affiliation>Kid Risk, Inc., Orlando, FL, USA. Electronic address: kimt@kidrisk.org.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>CC999999</GrantID><Acronym>ImCDC</Acronym><Agency>Intramural CDC HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NU2RGH001915</GrantID><Acronym>AA</Acronym><Agency>NIAAA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NU2RGH001915</GrantID><Acronym>ImCDC</Acronym><Agency>Intramural CDC HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>11</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Vaccine</MedlineTA><NlmUniqueID>8406899</NlmUniqueID><ISSNLinking>0264-410X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011055">Poliovirus Vaccine, Oral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011055" MajorTopicYN="N">Poliovirus Vaccine, Oral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017955" MajorTopicYN="Y">Poliovirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011051" MajorTopicYN="Y">Poliomyelitis</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004196" MajorTopicYN="N">Disease Outbreaks</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Dynamic modeling</Keyword><Keyword MajorTopicYN="N">Eradication</Keyword><Keyword MajorTopicYN="N">OPV</Keyword><Keyword MajorTopicYN="N">Outbreak response</Keyword><Keyword MajorTopicYN="N">Polio</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>4</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>9</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>10</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>4</Month><Day>3</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>19</Day><Hour>22</Hour><Minute>5</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>6</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36402659</ArticleId><ArticleId IdType="mid">NIHMS1905751</ArticleId><ArticleId IdType="pmc">PMC10284582</ArticleId><ArticleId IdType="doi">10.1016/j.vaccine.2022.10.060</ArticleId><ArticleId IdType="pii">S0264-410X(22)01336-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Tebbens RJD, Pallansch MA, Kew OM, C&#xe1;ceres VM, Jafari H, Cochi SL, et al. Risks of paralytic disease due to wild or vaccine-derived poliovirus after eradication. Risk Anal 2006;26(6):1471&#x2013;505.</Citation><ArticleIdList><ArticleId IdType="pubmed">17184393</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson KM, Tebbens RJD. Retrospective cost-effectiveness analyses for polio vaccination in the United States. Risk Anal 2006;26(6):1423&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">17184390</ArticleId></ArticleIdList></Reference><Reference><Citation>Duintjer Tebbens RJ, Pallansch MA, Kim J-H, Burns CC, Kew OM, Oberste MS, et al. Review: Oral poliovirus vaccine evolution and insights relevant to modeling the risks of circulating vaccine-derived polioviruses (cVDPVs). Risk Anal 2013;33(4):680&#x2013;702.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7890645</ArticleId><ArticleId IdType="pubmed">23470192</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalkowska DA, Pallansch MA, Thompson KM. Updated modelling of the prevalence of immunodeficiency-associated long-term vaccine-derived poliovirus (iVDPV) excreters. Epidemiol Infect 2019;147:e295.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6813650</ArticleId><ArticleId IdType="pubmed">31647050</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization Global Polio Eradication Initiative. Polio eradication and endgame Strategic Plan (2013&#x2013;2018)
http://polioeradication.org/wp-content/uploads/2016/07/PEESP_EN_A4.pdf; 2013.  [accessed
Jun 4, 2019].</Citation></Reference><Reference><Citation>Thompson KM, Kalkowska DA. Review of poliovirus modeling performed from 2000&#x2013;2019 to support global polio eradication. Expert Rev Vaccines 2020;19:661&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7497282</ArticleId><ArticleId IdType="pubmed">32741232</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson KM, Tebbens RJD. Current polio global eradication and control policy options: perspectives from modeling and prerequisites for oral poliovirus vaccine cessation. Expert Rev Vaccines 2012;11(4):449&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pubmed">22551030</ArticleId></ArticleIdList></Reference><Reference><Citation>Hampton LM, Farrell M, Ramirez-Gonzalez A, Menning L, Shendale S, Lewis I, et al. Cessation of trivalent oral poliovirus vaccine and introduction of inactivated poliovirus vaccine - Worldwide, 2016. MMWR 2016;65(35):934&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">27606675</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson KM, Duintjer Tebbens RJ. The case for cooperation in managing and maintaining the end of poliomyelitis: Stockpile needs and coordinated OPV cessation. Med J Med 2008;10:190.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2562150</ArticleId><ArticleId IdType="pubmed">18924642</ArticleId></ArticleIdList></Reference><Reference><Citation>Duintjer Tebbens RJ, Thompson KM. Poliovirus vaccination during the endgame: Insights from integrated modeling. Expert Rev Vaccines 2017;16 (6):577&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">28437234</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. Meeting of the Strategic Advisory Group of Experts on immunization, October 2015 - conclusions and recommendations. Wkly Epidemiol Rec 2015;90:681&#x2013;700.</Citation><ArticleIdList><ArticleId IdType="pubmed">26685390</ArticleId></ArticleIdList></Reference><Reference><Citation>Diop OM, Asghar H, Gavrilin E, Moeletsi NG, Benito GR, Paladin F, et al. Virologic Monitoring of Poliovirus Type 2 after Oral Poliovirus Vaccine Type 2 Withdrawal in April 2016 - Worldwide, 2016&#x2013;2017. Morb Mortal Wkly Rep 2017;66(20):538&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5657872</ArticleId><ArticleId IdType="pubmed">28542124</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper LV, Bandyopadhyay A, Gumede-Moeletsi N, Mach O, Mkanda P, Ndoutab&#xe9; M, et al. Risk factors for spread of vaccine-derived type 2 polioviruses in Africa following global withdrawal of trivalent oral poliovirus vaccine and impact of outbreak response with monovalent vaccine: a retrospective analysis of surveillance data. Lancet Infect Dis 2022;22:284&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8799632</ArticleId><ArticleId IdType="pubmed">34648733</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson KM. Polio eradication: what kind of world do we want?. Lancet Infect Dis 2022;22(2):161&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8504921</ArticleId><ArticleId IdType="pubmed">34648732</ArticleId></ArticleIdList></Reference><Reference><Citation>Macklin GR, O&#x2019;Reilly KM, Grassly NC, Edmunds WJ, Mach O, Santhana Gopala Krishnan R, et al. Evolving epidemiology of poliovirus serotype 2 following withdrawal of the serotype 2 oral poliovirus vaccine. Science 2020;368 (6489):401&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10805349</ArticleId><ArticleId IdType="pubmed">32193361</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalkowska DA, Pallansch MA, Cochi SL, Kovacs SD, Wassilak SGF, Thompson KM. Updated characterization of post-OPV cessation risks: Lessons from 2019 serotype 2 outbreaks and implications for the probability of OPV restart. Risk Anal 2021;41(2):320&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7814395</ArticleId><ArticleId IdType="pubmed">32632925</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization Global Polio Eradication Initiative. Circulating vaccine-derived poliovirus
https://polioeradication.org/wp-content/uploads/2022/09/weekly-polio-analyses-cVDPV-20220906.pdf; 2022.  [accessed
9 Sep, 2022].</Citation></Reference><Reference><Citation>World Health Organization. Meeting of the Strategic Advisory Group of Experts on immunization, April 2017 - conclusions and recommendations. Wkly Epidemiol Rec 2017;92:301&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">28580777</ArticleId></ArticleIdList></Reference><Reference><Citation>Duintjer Tebbens RJ, Thompson KM. Modeling the potential role of inactivated poliovirus vaccine to manage the risks of oral poliovirus vaccine cessation. J Infect Dis 2014;210:S485&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pubmed">25316871</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalkowska DA, Pallansch MA, Wilkinson A, Bandyopadhyay AS, Konopka-Anstadt JL, Burns CC, et al. Updated characterization of poliovirus outbreak response strategies for 2019&#x2013;2029: Impacts of the use of novel OPV2 strains. Risk Anal 2021;41:329&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7887065</ArticleId><ArticleId IdType="pubmed">33174263</ArticleId></ArticleIdList></Reference><Reference><Citation>Harutyunyan V QA, Pallansch M, Zipursky S, Woods D, Ottosen A, Vertefeuille J, Lewis I. Global oral poliovirus vaccine stockpile management as an essential preparedness and response mechanism for type 2 poliovirus outbreaks following global oral poliovirus vaccine type 2 withdrawal. Vaccine 2022; S0264-410X(22)00204-3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10427718</ArticleId><ArticleId IdType="pubmed">35282924</ArticleId></ArticleIdList></Reference><Reference><Citation>Duintjer Tebbens RJ, Pallansch MA, Wassilak SGF, Cochi SL, Thompson KM. Characterization of outbreak response strategies and potential vaccine stockpile needs for the polio endgame. BMC Infecti Dis 2016;16:137.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4806487</ArticleId><ArticleId IdType="pubmed">27009272</ArticleId></ArticleIdList></Reference><Reference><Citation>Duintjer Tebbens RJ, Pallansch MA, Cochi SL, Ehrhardt DT, Farag NH, Hadler SC, et al. Modeling poliovirus transmission in Pakistan and Afghanistan to inform vaccination strategies in undervaccinated subpopulations. Risk Anal 2018;38 (8):1701&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7879700</ArticleId><ArticleId IdType="pubmed">29314143</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson KM, Duintjer Tebbens RJ. The differential impact of oral poliovirus vaccine formulation choices on serotype-specific population immunity to poliovirus transmission. BMC Infect Dis 2015;15(1).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4574692</ArticleId><ArticleId IdType="pubmed">26382234</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalkowska DA, Pallansch MA, Cochi SL, Thompson KM. Updated characterization of poliovirus transmission in Pakistan and Afghanistan and the impacts of different outbreak response options. J Infect Dis 2021;224:1529&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8083227</ArticleId><ArticleId IdType="pubmed">33885734</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalkowska DA, Pallansch MA, Wassilak SGF, Cochi SL, Thompson KM. Serotype 2 oral poliovirus vaccine (OPV2) choices and the consequences of delaying outbreak response. Vaccine 2021. 10.1016/j.vaccine.2021.04.061. online May 14, 2021. In this issue.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2021.04.061</ArticleId><ArticleId IdType="pmc">PMC11027208</ArticleId><ArticleId IdType="pubmed">33994237</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson KM, Duintjer Tebbens RJ, Pallansch MA. Evaluation of response scenarios to potential polio outbreaks using mathematical models. Risk Anal 2006;26(6):1541&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">17184396</ArticleId></ArticleIdList></Reference><Reference><Citation>Duintjer Tebbens RJ, Pallansch MA, Cochi SL, Wassilak SGF, Thompson KM. An economic analysis of poliovirus risk management policy options for 2013&#x2013;2052. BMC Infect Dis 2015;15(1).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4582932</ArticleId><ArticleId IdType="pubmed">26404632</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson KM, Duintjer Tebbens RJ. Lessons from globally-coordinated cessation of serotype 2 oral poliovirus vaccine for the remaining serotypes. J Infect Dis 2017;216:S168&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5853947</ArticleId><ArticleId IdType="pubmed">28838198</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalkowska DA, Wassilak SGF, Cochi SL, Pallansch MA, Thompson KM. Global transmission of live polioviruses: Updated integrated dynamic modeling of the polio endgame. Risk Anal 2021;41:248&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7787008</ArticleId><ArticleId IdType="pubmed">31960533</ArticleId></ArticleIdList></Reference><Reference><Citation>Macadam AJ, Ferguson G, Stone DM, Meredith J, Knowlson S, Auda G, et al. Rational design of genetically stable, live-attenuated poliovirus vaccines of all three serotypes: relevance to poliomyelitis eradication. J Virol 2006;80 (17):8653&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1563845</ArticleId><ArticleId IdType="pubmed">16912313</ArticleId></ArticleIdList></Reference><Reference><Citation>Bandyopadhyay AS, Garon J, Seib K, Orenstein WA. Polio vaccination: past, present and future. Future Microbiol 2015;10(5):791&#x2013;808.</Citation><ArticleIdList><ArticleId IdType="pubmed">25824845</ArticleId></ArticleIdList></Reference><Reference><Citation>Duintjer Tebbens RJ, Thompson KM. The potential benefits of a new poliovirus vaccine for long-term poliovirus risk management. Future Microbiol 2016;11 (12):1549&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">27831742</ArticleId></ArticleIdList></Reference><Reference><Citation>S&#xe1;ez-Llorens X, Bandyopadhyay AS, Gast C, Leon TD, DeAntonio R, Jimeno J, et al. Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in children and infants: two clinical trials. The Lancet 2021;397(10268):27&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7811205</ArticleId><ArticleId IdType="pubmed">33308427</ArticleId></ArticleIdList></Reference><Reference><Citation>De Coster I, Leroux-Roels I, Bandyopadhyay AS, Gast C, Withanage K, Steenackers K, et al. Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in healthy adults: two clinical trials. The Lancet 2021;397 (10268):39&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7811203</ArticleId><ArticleId IdType="pubmed">33308429</ArticleId></ArticleIdList></Reference><Reference><Citation>Konopka-Anstadt JL, Campagnoli R, Vincent A, Shaw J, Wei L, Wynn NT, et al. Development of a new oral poliovirus vaccine for the eradication end game using codon deoptimization. npj Vaccines 2020;5:26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7083942</ArticleId><ArticleId IdType="pubmed">32218998</ArticleId></ArticleIdList></Reference><Reference><Citation>Gast C, Bandyopadhyay AS, S&#xe1;ez-Llorens X, De Leon T, DeAntonio R, Jimeno J, et al. Fecal shedding of two novel live attenuated oral poliovirus type 2 vaccines candidates by healthy bOPV/IPV-vaccinated infants: two randomized clinical trials. J Infect Dis 2022;226(5):852&#x2013;61. 10.1093/infdis/jiab507.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiab507</ArticleId><ArticleId IdType="pmc">PMC9470102</ArticleId><ArticleId IdType="pubmed">34610135</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. cVDPV2 outbreaks and the type 2 novel oral poliovirus vaccine (nOPV2)
https://polioeradication.org/wp-content/uploads/2022/01/GPEI_cVDPV2-nOPV2_Factsheet_13-Jan-2022-EN.pdf; 2022.  [accessed
Feb 24, 2022].</Citation></Reference><Reference><Citation>World Health Organization. Global Advisory Committee on Vaccine Safety, 17 September 2021. Wkly Epidemiol Rec 2022;97:17&#x2013;24.</Citation></Reference><Reference><Citation>Global Polio Eradication Initiative. nOPV2: Clinical development summary updated June 2022
https://polioeradication.org/wp-content/uploads/2022/06/nOPV2-Clinical-Development-Summary_June-2022-Update_Final-EN.pdf; 2022.  [accessed
11 Aug 2022].</Citation></Reference><Reference><Citation>World Health Organization. Meeting of the Strategic Advisory Group of Experts on immunization, October 2021: conclusions and recommendations. Wkly Epidemiol Rec 2021;96:613&#x2013;32.</Citation></Reference><Reference><Citation>Kalkowska DA, Voorman A, Pallansch MA, Wassilak SGF, Cochi SL, Badizadegan K, et al. The impact of disruptions caused by the COVID-19 pandemic on global polio eradication. Vaccine 2021:S0264-410X(21)00473-4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10045205</ArticleId><ArticleId IdType="pubmed">33962838</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization Global Polio Eradication Initiative. Standard operating procedures: Responding to a poliovirus event or outbreak: Part 2: Protocol for poliovirus type 2
http://polioeradication.org/wp-content/uploads/2018/01/pol-sop-responding-polio-event-outbreak-part2-20180117.pdf; 2018.  [accessed
August 20, 2020].</Citation></Reference><Reference><Citation>World Health Organization Global Polio Eradication Initiative. Standard operating procedures: Responding to a poliovirus event or outbreak: Version 3.1, March 2020
http://polioeradication.org/wp-content/uploads/2020/04/POL-SOP-V3.1-20200424.pdf; 2020.  [accessed
August 20, 2020].</Citation></Reference><Reference><Citation>World Health Organization Global Polio Eradication Initiative. Polio eradication and endgame strategic plan (2019&#x2013;2023)
https://polioeradication.org/wp-content/uploads/2019/06/english-polio-endgame-strategy.pdf; 2019.  [accessed
Jun 4, 2019].</Citation></Reference><Reference><Citation>World Health Organization Global Polio Eradication Initiative. Strategy for the response to type 2 circulating vaccine-derived poliovirus 2020&#x2013;2021: Addendum to the Polio eradication and endgame strategic plan (2019&#x2013;2023)
http://polioeradication.org/wp-content/uploads/2020/04/Strategy-for-the-response-to-type-2-circulating-Vaccine-Derived-Poliovirus-20200406.pdf; 2020.  [accessed
Mar 10, 2020].</Citation></Reference><Reference><Citation>World Health Organization Global Polio Eradication Initiative. Polio eradication strategy 2022&#x2013;2026: Delivering on a promise
https://polioeradication.org/wp-content/uploads/2021/06/polio-eradication-strategy-2022-2026-pre-publication-version-20210609.pdf; 2021.  [accessed
Jun 11, 2021].</Citation></Reference><Reference><Citation>World Health Organization. WHO/UNICEF estimated coverage time series
http://www.who.int/entity/immunization/monitoring_surveillance/data/coverage_estimates_series.xls; 2020.  [accessed
Jul 24, 2020].</Citation></Reference><Reference><Citation>Kalkowska DA, Badizadegan K, Thompson KM. Modeling scenarios for ending poliovirus transmission in Pakistan and Afghanistan. Risk Anal 2022. 10.1111/risa.13983. online June 23, 2022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/risa.13983</ArticleId><ArticleId IdType="pmc">PMC9780402</ArticleId><ArticleId IdType="pubmed">35739080</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. Wild poliovirus list: List of wild poliovirus by country and year
https://polioeradication.org/wp-content/uploads/2022/09/weekly-polio-analyses-WPV-20220906.pdf; 2022.  [accessed
9 Sep, 2022].</Citation></Reference><Reference><Citation>Duintjer Tebbens RJ, Thompson KM. Polio endgame risks and the possibility of restarting the use of oral poliovirus vaccine. Expert Rev Vaccines 2018;17:739&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6168953</ArticleId><ArticleId IdType="pubmed">30056767</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Damme P, De Coster I, Bandyopadhyay AS, Revets H, Withanage K, De Smedt P, et al. The safety and immunogenicity of two novel live attenuated monovalent (serotype 2) oral poliovirus vaccines in healthy adults: a double-blind, single-centre phase 1 study. Lancet 2019;394:148&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6626986</ArticleId><ArticleId IdType="pubmed">31174831</ArticleId></ArticleIdList></Reference><Reference><Citation>Duintjer Tebbens RJ, Pallansch MA, Alexander JP, Thompson KM. Optimal vaccine stockpile design for an eradicated disease: Application to polio. Vaccine 2010;28:4312&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pubmed">20430122</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization Global Polio Eradication Initiative. Standard operating procedures - Responding to a poliovirus event or outbreak &#x2013; version 4
https://polioeradication.org/wp-content/uploads/2022/07/Standard-Operating-Procedures-For-Responding-to-a-Poliovirus-Event-Or-Outbreak-20220807-EN-Final.pdf; 2022.  [accessed
20 Aug, 2022].</Citation></Reference><Reference><Citation>Shaw AG, Cooper LV, Gumede N, Bandyopadhyay AS, Grassly NC, Blake IM. Time taken to detect and respond to polio outbreaks in Africa and the potential impact of direct molecular detection and nanopore sequencing. J Infect Dis 2022;226:453&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9417130</ArticleId><ArticleId IdType="pubmed">34623444</ArticleId></ArticleIdList></Reference><Reference><Citation>Estivariz CF, Pallansch MA, Anand A, Wassilak SG, Sutter RW, Wenger JD, et al. Poliovirus vaccination options for achieving eradication and securing the endgame. Current Opinion in Virology 2013;3:309&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10395005</ArticleId><ArticleId IdType="pubmed">23759252</ArticleId></ArticleIdList></Reference><Reference><Citation>Duintjer Tebbens RJ, Hampton LM, Thompson KM. Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: Risks of potential non-synchronous cessation. BMC Infect Dis 2016;16:237.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4888482</ArticleId><ArticleId IdType="pubmed">27246198</ArticleId></ArticleIdList></Reference><Reference><Citation>Duintjer Tebbens RJ, Hampton LM, Thompson KM. Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: Risks of inadvertent trivalent oral poliovirus vaccine use. BMC Infect Dis 2016;16:231.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4888482</ArticleId><ArticleId IdType="pubmed">27246198</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization Global Polio Eradication Initiative. GPEI statement on WPV1 in Malawi
https://polioeradication.org/news-post/gpei-statement-on-wpv1-in-malawi/; 2022.  [accessed
Feb 22, 2022].</Citation></Reference><Reference><Citation>Duintjer Tebbens RJ, Hampton LM, Wassilak SGF, Pallansch MA, Cochi SL, Thompson KM. Maintenance and intensification of bivalent oral poliovirus vaccine use prior to its coordinated global cessation. J Vaccines Vaccination 2016;7:340.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5497833</ArticleId><ArticleId IdType="pubmed">28690915</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalkowska DA, Thompson KM. Expected implications of globally-coordinated cessation of serotype 3 oral poliovirus vaccine (OPV) before serotype 1 OPV. Risk Anal 2021;41:312&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7887090</ArticleId><ArticleId IdType="pubmed">32936466</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson KM, Kalkowska DA, Duintjer Tebbens RJ. Managing population immunity to reduce or eliminate the risks of circulation following the importation of live polioviruses. Vaccine 2015;33:1568&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7907970</ArticleId><ArticleId IdType="pubmed">25701673</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>